[one week king] the country of high blood pressure and diabetes will pay for your treatment! The decline of purchase volume of gifei for Nietzsche leads to a good "play" of expanding the capacity of centralized mining; Baiji Shenzhou responds to "shorting": we are "worthy of our hearts"

In the future, the "high blood pressure" and "diabetes" countries will pay for your treatment! 2 The "rattan" of medicine has affected the hearts of 4000 pharmaceutical companies; 3 The decline of purchase volume of gifei for Nietzsche leads to a good "play" of expanding the capacity of centralized procurement; 4 Baiji Shenzhou's response to "shorting": "no shame in the heart" The General Administration wants to hear that in the future, the "high blood pressure" and "diabetes" countries will pay for your treatment! On September 11, Premier Li Keqiang presided over the executive meeting of the State Council, which decided to issue reimbursement policies for medical insurance for urban and rural residents in outpatient clinics of hypertension and diabetes, reducing the burden on hundreds of millions of patients, the news broadcast reported We will further promote the integrated development of medical and nursing services to better meet the health and pension needs of the elderly At the same time, it was decided at the meeting that for more than 300 million patients with hypertension and diabetes who participated in the basic medical insurance for urban and rural residents, their outpatient medication within the scope of the national basic medical insurance drug catalog should be included in the medical insurance payment, and the reimbursement proportion should be increased to more than 50% The specific implementation situation can be adjusted according to local conditions, and the implementation effect should be enhanced At the meeting, it was emphasized to promote domestic antihypertensive and hypoglycemic drugs to reduce prices and improve quality, to implement the long prescription system, and to take multiple measures to reduce the burden on patients This is also conducive to strengthening prevention and reducing the incidence rate of serious diseases, and is conducive to the sustainability of medical insurance funds It also determines the specific implementation measures to further promote the development of medical and nursing cooperation The first is to simplify the examination and approval; the second is to improve the price mechanism and implement the "one window" examination and approval; the third is to encourage the cooperation between pension institutions and medical and rehabilitation institutions; the fourth is to implement the tax, land and other policies supporting the combination of medical and nursing; the fifth is to develop medical and nursing insurance and increase the types of commercial insurance available to the elderly In fact, as early as this year's "two sessions", Li Keqiang proposed in the "government work report" that "we should do a good job in the prevention and treatment of common chronic diseases, and include outpatient drugs such as hypertension and diabetes into the medical insurance reimbursement" In April of this year, the State Council's opinions on the implementation of the division of labor of key work departments made it clear that the national health insurance bureau is responsible for the implementation of "including outpatient drugs such as hypertension and diabetes into medical insurance reimbursement" In May this year, the State Medical Security Bureau and the Ministry of finance also proposed to include outpatient drugs such as hypertension and diabetes into the reimbursement of medical insurance Now this policy of benefiting the people has finally entered the implementation stage Local governments are looking forward to actively cooperating with the state in implementing policies Zhejiang, Yunnan and Shaanxi made corresponding implementation measures last year It is also a positive way for local governments to explore before the policies are implemented To some extent, it shows that both national and local governments attach great importance to it On September 11, the State Food and Drug Administration organized and carried out the preparation of drug traceability standards to implement the guidance of the State Food and Drug Administration on the construction of drug informatization traceability system, promote the construction of drug informatization traceability system Recently, 5 draft standards have been completed for public comment In principle, drug traceability is a system that supervises the whole process of drug production and circulation through the electronic supervision system of drugs In case of any problem, it can be a system of responsibility traceability As early as April 28, 2016, the State Food and Drug Administration issued the opinions on further improving food and drug traceability system (Draft for comments) It is pointed out that the traceability system of food and drug is an important part of the quality management system of food and drug Establishing food and drug traceability system is the main responsibility of enterprises This open consultation for the public to some extent shows the national government's attention and determination to strengthen drug supervision Don't worry! On September 11, the State Medical Security Bureau released two suggestions for the NPC session 1、 We will improve the centralized bidding and purchase of drugs in public hospitals and improve the work related to medical insurance The State Medical Insurance Bureau said that the implementation effect of the centralized drug purchase program is basically good, the pilot operation is stable, and the operation effect is better than expected It has successfully promoted the substitution of generic drugs Next, the relevant departments of the state will focus on the following three aspects: 1 Continue to do a solid job in organizing and implementing the pilot project We will strengthen the monitoring and guidance of the pilot areas, ensure the quality and supply of the selected drugs in the pilot areas, promote the priority use of the selected drugs, and enable patients to fully enjoy the dividends of the reform; 2 We will start to expand the scope of the pilot implementation as soon as possible, so that the reform will benefit more people; 3 We will optimize and improve the drug bidding and procurement system according to the evaluation results of the pilot sites and suggestions from all aspects It is emphasized that in the development of medical insurance standards, relevant ideas should be carefully sorted out, and on the basis of in-depth summary of local experience and extensive consultation with all parties, the policy of medical insurance payment standards should be gradually established in line with China's actual situation At the same time, in the direction of medicine shortage, the monitoring and early warning mechanism of medicine shortage price and purchase information should be established to allow enterprises to directly link their quotations to the Internet and medical institutions to purchase independently To ensure the reasonable profit of the enterprise 2、 As for the establishment of the time limit for the hospital to pay the advance medical insurance fund, the State Medical Insurance Bureau said that, on the whole, most localities can allocate medical insurance expenses to designated medical institutions according to the time limit stipulated in the agreement, but some localities are in arrears According to the above situation, the medical insurance department will guide the local government to further improve the total amount control and agreement management, revise the agreement model, establish a long-term mechanism, standardize the time limit of medical insurance expenses allocation, and urge the local government to implement it At the same time, we should further improve the level of medical insurance financing, improve the financial accounting system of medical insurance fund, strengthen the equal consultation between medical insurance agencies and hospitals, and properly solve the problem of delinquency of medical insurance funds in hospitals In addition, we will continue to carry out the campaign against fraud and insurance, and strengthen the supervision of medical insurance funds through special treatment of fraud and insurance, full coverage of designated medical institutions and expansion of flight inspection And encourage commercial insurance companies to develop marketable insurance products and services to meet the medical security needs of the people We will explore ways to entrust commercial insurance institutions to undertake serious illness insurance in the form of government purchase services, give full play to the advantages of commercial insurance institutions, and improve the efficiency of system operation The establishment of cancer center with industry hot news and anticancer medicine becoming the "first brother" will soon be ready for the national health and Health Commission to organize and formulate the "National Cancer regional medical center setting standard", which outlines the appearance of a qualified national cancer regional medical center with specific quantitative standards for everyone It is emphasized that as a national cancer regional medical center, it is necessary to have a strong medical service ability, and the third grade a tumor specialized hospital or the third grade a comprehensive hospital with the corresponding tumor specialized ability is the foundation In this way, it not only achieves the purpose of hierarchical diagnosis and treatment, but also focuses on the development of cancer related industries In addition, in a recent report on the health status of Tianjin residents, Tianjin drug regulatory bureau also mentioned that during 2018, malignant tumors were the second leading cause of death of residents, accounting for 24.87% It can be seen that nausea and tumor have seriously threatened people's life and health, and the masses have become the focus of the national medical cause At the same time, major pharmaceutical companies have also successfully grasped the trend of the times, invested heavily in research projects of tumor treatment, and endless tumor drugs have sprung up on the market The fire PD-1 is the best example Now, once this policy is implemented, it will greatly inspire the confidence of relevant pharmaceutical manufacturers, and also to a certain extent promote the progress of tumor business, believing in the future Tumor drugs will surpass others and become the "first brother" of the drug market On September 6 and 8, the Shanghai joint purchasing office significantly reduced the purchase volume of gefitinib and pemetrexed, among which the most influential one was gefitinib, with a direct decrease of 45% However, to a certain extent, it also reduces the purchase volume of three provinces with little difference to one province directly At present, the purchase volume of Henan Province is twice that of Shandong Province, which ranks second, so that the purchase volume of the first ranking will be much more than the latter two From the existing data analysis, the first ranking is expected to purchase nearly 142W pieces, accounting for 54%, equivalent to the sum of the remaining two So how to price becomes the key to No.1 At present, AstraZeneca won 547 yuan last year; Qilu pharmaceutical won 498 yuan from March to June 2019; and Zhengda Tianqing Shandong Province won 460 yuan Although this is not the final pricing of the enterprise, to some extent, it also reflects the best profit market proportion of the enterprise for drugs, that is, the best cost performance in the enterprise's mind According to the provisions of the centralized drug purchase document of the alliance region, those with lower prices are preferred to purchase, and those with the same price are preferred to choose last year If Zhengda Tianqing and Qilu want to win the market and defeat AstraZeneca in this purchase, they must be prepared for a large amount of price reduction, but they can't kill a thousand enemies and lose 800 by themselves So how to price becomes the next focus of the enterprise Finally, it has to be said that the decline in the purchase of Geoffrey for Nietzsche is really the best play to watch in the expansion of the collection Who can sing to the end, we will see Baiji Shenzhou responds to "shorting": on September 9, the leadership of Baiji Shenzhou responded in detail to a series of accusations made in a recent report issued by jcapital Research (hereinafter referred to as "meiqijin") In the previous report, meiqijin said it was short of Baiji Shenzhou and accused it of overstating the sales volume of three products purchased from Xinji in the Chinese market by 60% in the fourth quarter of 2017 In addition, the report also pointed out that the R & D cost of Baiji Shenzhou is too high, and there is a lack of commercialized products in the pipeline Then, Baiji Shenzhou dived in both Hong Kong stock market and American stock market, and was frustrated for two consecutive days By the end of that day, the market value of Baiji Shenzhou's U.S shares and Hong Kong shares had shrunk by US $1.2 billion and HK $8.2 billion respectively Baiji Shenzhou is suspected that 60% of its sales are fraudulent, and it has overstated its sales by about 33% Baiji Shenzhou directly released the sales data reported by more than 420 dealers, and said that the revenue growth of Baiji Shenzhou in the past two years was due to the successful management and commercialization strategy In addition, after obtaining the three new drugs, the business team of Baiji Shenzhou increased significantly, and the plan covered 800-1000 hospitals As for the behavior of high R & D cost and excessive waste, or the problem of false report of expenditure, Ou Lei Qiang, the co-founder of Baiji Shenzhou, pointed out that the R & D cost of Baiji Shenzhou is not the highest, which is below the average level, while most companies in the same commercialization stage are above the level As for the flow of funds, 75% of the raised funds will be used for the research and development of three core anti-tumor drugs in the late clinical stage, especially a large number of global phase III clinical trials O'reiqiang believes that whether foot products can be approved first is not the most important, but whether they can get a large number of indications quickly With these indications into the reimbursement catalog, only through reimbursement can a large number of patients be reached At present, everything Baiji has done is for this purpose, which is the same goal of the company Meet on a narrow road, the brave win, the first imitation horse